Our Company
Our mission is to change the standard of care for patients with immunologic and rare diseases. We are developing multiple novel biologic molecules toward this end.
Our lead late-stage clinical candidate is atacicept:
- Fully humanized TACI-Fc fusion protein that inhibits the two cytokines, BAFF and APRIL, that cause B cells and plasma cells to produce disease-causing antibodies
- Potential best- and first-in-class dual BAFF/APRIL B cell modulator for IgA Nephropathy (IgAN), a B cell-mediated kidney disease that often progresses to kidney failure despite optimized supportive care
- Demonstrated sustained eGFR stabilization through 72 weeks in the ORIGIN Phase 2b clinical trial for IgAN
- ORIGIN 3, a pivotal Phase 3 clinical trial, initiated June 2023
- Target profile: at-home self-administration by subcutaneous once weekly autoinjector
We also hold worldwide global rights to MAU868:
- A monoclonal antibody that neutralizes infection by blocking BK virus (BKV) binding to host cells
- Phase 2 clinical trial showed MAU868 was well tolerated and showed clinically meaningful reductions in BK antiviral activity through 36 weeks in kidney transplant patients with BK viremia
- No BK-specific treatment currently available
- Target profile: monthly IV administration